No­var­tis toss­es more US PD-1 sub­mis­sion plans and an­oth­er an­ti-CD40 drug in­di­ca­tion

Buried in No­var­tis’ third quar­ter re­port were a few key in­di­ca­tion drops.

First, No­var­tis is no longer plan­ning to sub­mit tislelizum­ab for FDA ap­proval in first-line na­sopha­ryn­geal can­cer or first-line non-small cell lung can­cer along­side chemother­a­py — mark­ing two more US reg­u­la­to­ry set­backs for the PD-1 check­point in­hibitor for which No­var­tis gave BeiGene $650 mil­lion for US and ex-Chi­na rights.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER